Blogs

Immune Monitor - March 2026

By SITC Communications posted 17 days ago
0 comments

SITC Publishes Renal Cell Carcinoma Clinical Practice Guideline version 3.0

By Thomas Martin posted 19 days ago
0 comments

SITC Publishes Expert Insights on ICI-Related irAE Survivorship Care

By JITC Publications posted 21 days ago
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma

By SITC Communications posted 21 days ago
0 comments

JITC Digest March 2026

By JITC Publications posted 26 days ago
0 comments

SITC on Capitol Hill!

By SITC Advocacy posted 03-11-2026
0 comments

Announcing the publication of “Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles” manuscript

By SITC Advocacy posted 03-10-2026
0 comments

Oncology News Burst from the FDA: FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma

By SITC Communications posted 03-06-2026
0 comments

Immune Monitor - February 2026

By SITC Communications posted 02-26-2026
0 comments

JITC Digest February 2026

By JITC Publications posted 02-18-2026
0 comments

Immune Monitor - January 2026

By SITC Communications posted 01-29-2026
0 comments

Call for Comment: SITC Acute Leukemia CPG v2.0 Until Feb. 16

By Chuck Kolawole posted 01-28-2026
0 comments

JITC Digest January 2026

By JITC Publications posted 01-21-2026
0 comments

Immune Monitor - December 2025

By SITC Communications posted 01-06-2026
0 comments

JITC Digest December 2025

By JITC Publications posted 12-17-2025
0 comments

2025 ESMO IO Scientific Highlights

By Keegan Mager posted 12-12-2025
0 comments

SITC Hosts "AI, Upcoming Technologies, and Potential Applications: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 12-10-2025
0 comments

NEW! Myeloid Cells in Immuno-Oncology

By JITC Publications posted 12-02-2025
0 comments

Oncology News Burst from the FDA: FDA Approves Durvalumab with FLOT for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

By SITC Communications posted 12-01-2025
0 comments

Immune Monitor - November 2025

By SITC Communications posted 11-25-2025
0 comments